News & Perspective

Nov 17, 2017

Nov 17, 2017

ASP Scan (Weekly) for Nov 17, 2017

Primary care stewardship
No-touch superbug disinfection
Surgical antimicrobial prescribing
Ceftriaxone-resistant gonorrhea
E coli ST131
Single-room ICU design
ECDC CRE guidance
European research funding
Optimal MDR-TB treatment
Real-time resistance tracker
Salmonella in calves
Drug-resistant malaria controversy
US AMR progress
Antimicrobial use in Northern Ireland
Resistance in space
Nov 17, 2017

Stewardship / Resistance Scan for Nov 17, 2017

Primary care stewardship
No-touch superbug disinfection
Surgical antimicrobial prescribing

Dec 29, 2016

Dec 29, 2016

News Scan for Dec 29, 2016

Saudi MERS cases
H7N9 in China, Hong Kong
Salmonella Oslo outbreak
Antibiotic-free chicken
Cholera in Yemen

Dec 19, 2016

Dec 19, 2016

News Scan for Dec 19, 2016

H7N9 in Hong Kong
Bacteriophage study
Chikungunya update

Jul 29, 2016

Jul 29, 2016

ASP Scan (Weekly) for Jul 29, 2016

Compliance and MRSA clearance
Costs of MRSA care
MCR-1 in Hong Kong
CRE risk factors
Drug-resistant C coli cluster
Safety labels for fluoroquinolones
Antibiotic overuse for asthma

Jul 28, 2016

Jul 28, 2016

News Scan for Jul 28, 2016

MCR-1 in Hong Kong
College mumps response

Apr 19, 2016

Apr 19, 2016

News Scan for Apr 19, 2016

Public health funding
Saudi MERS cases
More chikungunya
New H7N9 cases
MRSA in athletes

Jan 05, 2016

Jan 05, 2016

News Scan for Jan 05, 2016

MCR-1 in Canada
Medical countermeasures for kids
Impact of minor flu strains

May 28, 2013

May 28, 2013

Researchers find easy development of H7N9 Tamiflu resistance

(CIDRAP News) – Antiviral drugs such as oseltamivir (Tamiflu) are useful for treating H7N9 influenza infections, but there are worrisome signs that resistance can easily develop when patients take the drug, which can lead to a poor prognosis, researchers from China and Hong Kong reported today.

Pages

Sort Results

 

Narrow results

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»